What is the correct method for administering vancomycin rectally as an enema?

Rectal Vancomycin Administration for Fulminant C. difficile Infection

For patients with fulminant C. difficile infection and ileus, administer vancomycin 500 mg diluted in 500 mL of normal saline every 6 hours as a retention enema, using an 18F Foley catheter with a 30-cc balloon inflated in the rectum, with the solution retained for 60 minutes before unclamping. 1, 2

Clinical Context and Indications

Rectal vancomycin is specifically indicated for fulminant C. difficile infection when ileus is present, preventing oral vancomycin from reaching the colon 1. The 2021 IDSA/SHEA guidelines define fulminant CDI by the presence of hypotension/shock, ileus, or megacolon 1.

Step-by-Step Administration Protocol

Preparation Phase

• Dose: Vancomycin 500 mg
• Diluent: 500 mL of normal saline (physiologic saline) 2
• Equipment: 18 French Foley catheter with 30-cc balloon 2
• Mix vancomycin powder thoroughly in the saline solution until completely dissolved

Insertion and Administration

1. Position the patient in left lateral decubitus position (Sims position) to facilitate retention
2. Insert the 18F Foley catheter into the rectum approximately 10-15 cm
3. Inflate the balloon with 30 cc of water to create a seal and prevent immediate expulsion 2
4. Instill the 500 mL vancomycin solution slowly through the catheter
5. Clamp the catheter immediately after instillation
6. Retain for 60 minutes with the catheter clamped 2
7. Unclamp and remove the catheter after the retention period

Frequency

• Every 6 hours (four times daily) 1, 2

Evidence-Based Rationale

The guideline recommendation evolved from clinical experience showing that higher volumes and higher doses demonstrate superior efficacy 2. A 2019 systematic review found that smaller volumes (100 mL) with lower doses (125-250 mg) showed no efficacy, while 500 mg in 500 mL with retention demonstrated clear clinical benefit 2.

The retention enema technique is critical because it:

• Maximizes contact time between vancomycin and colonic mucosa
• Ensures adequate distribution throughout the colon
• Prevents immediate expulsion that would reduce drug exposure

Critical Combination Therapy

Rectal vancomycin must be combined with:

• Oral vancomycin 500 mg four times daily (or via nasogastric tube if tolerated) 1
• Intravenous metronidazole 500 mg every 8 hours 1

This triple-route approach is essential in fulminant disease because ileus prevents oral medications from reaching the colon, and IV metronidazole alone has inferior colonic penetration compared to enteral vancomycin 1.

Common Pitfalls to Avoid

1. Using inadequate volume: The 2017 IDSA guidelines mentioned 100 mL, but evidence shows 500 mL is superior for distribution 2
2. Omitting the retention catheter: Simple instillation without balloon retention leads to immediate expulsion and treatment failure 2
3. Insufficient retention time: Less than 60 minutes reduces mucosal contact and efficacy 2
4. Using rectal vancomycin as monotherapy: Always combine with IV metronidazole in fulminant cases 1
5. Forgetting to attempt oral/NG vancomycin: Even with ileus, attempt enteral administration as the primary route 1

Alternative Scenarios

Rectal vancomycin may also be considered in non-fulminant cases when:

• Oral administration is impossible (e.g., Hartmann's pouch, ileostomy, colon diversion) 3
• Severe CDI with inability to take oral medications 3

However, in these situations without ileus, standard oral vancomycin 125 mg four times daily remains preferred if feasible 1.

Monitoring Considerations

While systemic absorption of rectal vancomycin is generally minimal, critically ill patients with severe colitis can have unpredictable absorption 4. In patients with renal dysfunction receiving both IV and rectal vancomycin, consider monitoring serum vancomycin levels if nephrotoxicity concerns arise, though this is not routinely necessary for rectal administration alone.

FDA Labeling Context

Note that the FDA-approved vancomycin injection formulation is labeled only for intravenous use 5. Rectal administration represents off-label use supported by clinical guidelines and evidence for C. difficile infection management, not by the drug manufacturer's labeling.